08:51 AM EDT, 08/26/2024 (MT Newswires) -- Vericel ( VCEL ) said Monday that the US Food and Drug Administration has approved its supplemental Biologics License Application, which expands the indications for its collagen membrane treatment MACI to include repair of symptomatic cartilage defects in the knee up to 4 square centimeters in size.

The company said MACI, which is now available commercially, is the first FDA-approved restorative product that uses tissue engineering to grow cells using healthy tissue from the patient's own knee.

Shares of the sports-medicine focused biotech firm were up 3.8% in recent Monday's premarket activity.

Price: 51.14, Change: +1.85, Percent Change: +3.75